Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey.

Zhdanava, Maryia; Starr, H Lynn; Lefebvre, Patrick; Totev, Todor I; Shah, Aditi; Sheng, Kristy; Pilon, Dominic

Zhdanava, Maryia; Starr, H Lynn; Lefebvre, Patrick; Totev, Todor I; Shah, Aditi; Sheng, Kristy; Pilon, Dominic.

Afiliación

Zhdanava M; Analysis Group, Inc, Montréal, Quebec, Canada.
Starr HL; Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
Lefebvre P; Analysis Group, Inc, Montréal, Quebec, Canada.
Totev TI; Analysis Group, Inc, Boston, MA, USA.
Shah A; Analysis Group, Inc, Montréal, Quebec, Canada.
Sheng K; Analysis Group, Inc, Menlo Park, CA, USA.
Pilon D; Analysis Group, Inc, Montréal, Quebec, Canada.

Neuropsychiatr Dis Treat ; 18: 1479-1493, 2022.

Article en En | MEDLINE | ID: mdl-35910684

Palabras clave

COVID-19; healthcare providers; long-acting injectable antipsychotics; prescribing patterns; schizophrenia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Neuropsychiatr Dis Treat Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google